James R. Sulat

Insider Reports History

Entity
Individual
Signature
/s/ Mark Tyndall, Attorney-in-Fact
All insider transactions
Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date

Holdings reported by James R. Sulat:

Stock Role Class Num Shares Value Price $ Report Date Ownership
Arch Therapeutics, Inc. Director Stock Option (right to buy) 250K Sep 27, 2021 Direct
EXICURE, INC. Director Employee Stock Option (right to buy) 50K Jun 13, 2022 Direct
Mallinckrodt plc Director Ordinary Shares 0 $37.50 Nov 14, 2023 Direct

Insider Reports Filed by James R. Sulat

Symbol Company Period Transactions Value $ Form Type Date Filed Role
MNKTQ Mallinckrodt plc Nov 14, 2023 1 $0 4 Nov 16, 2023 Director
MNK Mallinckrodt plc Jun 16, 2023 2 -$4.04K 4 Jun 29, 2023 Director
MNK Mallinckrodt plc Mar 14, 2023 2 $254K 4 Mar 16, 2023 Director
MNK Mallinckrodt plc Jan 3, 2023 1 $0 4 Jan 5, 2023 Director
MNKPF Mallinckrodt plc Aug 16, 2022 1 $0 4 Sep 14, 2022 Director
MNKPF Mallinckrodt plc Jul 1, 2022 1 $0 4 Jul 6, 2022 Director
MNKPF Mallinckrodt plc Jun 16, 2022 0 $0 3 Jun 24, 2022 Director
XCUR EXICURE, INC. Jun 13, 2022 1 $0 4 Jun 15, 2022 Director
ARTH Arch Therapeutics, Inc. Sep 27, 2021 2 $0 4 Oct 1, 2021 Director
XCUR EXICURE, INC. Jun 2, 2021 1 $0 4 Jun 4, 2021 Director